NLSP is in phase 2a of their Narcolepsy trials for their development of innovative therapies for people with rare complex nervous system disorders.
Products abilities are promising , trials are going well , and they just appointed a New CFO
Chad Hellman – he has a good track record amd if there's 1 thing I know as a SQUEEZE CANDIDATE WHO BETTER THAN FOR US TO PUMP SOME MONEY WITH A CHAD.
I know pharmaceutic plays xan be risky in the sense that “if they fail a trial or something doesn't pass” then usually these stocks go down but that's not the play.
THE PLAY IS , we've got 60 days before any trial update/changes that impact shareholder value and this stock HAS AN EXTREMELY LOW CAP – hence the volatility and THISMORNING I WATCHED IT GO UP 10% ON 1K VOLUME.
BUYING PRESSURE WILL SEND THIS TO THE MOON
.60 A SHARE , THIS IS A SHORT SQUEEZE.
I LIKE THE STOCK. I BUY THE STOCK AND HOT POTATO HALF MY Holding , LETS GO!!!
TL/DR : PHASE 2A – NEW CFO WITH GOOD TRACK RECORD – MOVES BIG WITH BUYING PRESSURE – NO WALL TELL 1.86 – PRICE TARGET ON Mrkt Wtch 8$ – AVERAGE PRICE TARGET ON T-R 12$ . ITS READY TO GO
Leave a Reply